Interleukin 2 News and Research

RSS

Research on inflammasomes lays foundations for developing new RA treatments

Patients with more or less severe forms of rheumatoid arthritis (RA) may have the same painful symptoms, but does this mean that the cause of their illness is the same? And therefore that they should all receive the same treatment? Scientists at VIB and Ghent University have demonstrated with their research into inflammasomes that RA should be considered as a syndrome rather than a single disease.

2 Jul 2014

Researchers find unique cell type that can protect against uveitis

Researchers at the National Eye Institute (NEI) have found a unique cell type that, in tests on mice, can protect against uveitis—a group of inflammatory diseases that affect the eye and can cause vision loss.

1 Jul 2014

Host-directed therapy: A new type of TB treatment

In a new study published in Nature, scientists describe a new type of tuberculosis (TB) treatment that involves manipulating the body's response to TB bacteria rather than targeting the bacteria themselves, a concept called host-directed therapy.

28 Jun 2014

Interactions with other infections can trigger herpes virus to reactivate, shows research

The famous slogan is "A diamond is forever," but that phrase might be better suited to herpes: Unlike most viruses, which succumb to the immune system's attack, herpes remains in the body forever, lying in wait, sometimes reactivating years later.

27 Jun 2014

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals Incorporated announced the signing of an exclusive global license agreement with TG Therapeutics, Inc. for the development and commercialization of Ligand's Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors.

24 Jun 2014

Mechanisms of recurrent bacteria AOM in children under scrutiny

The immune response in young children with bacterial acute otitis media differs between individuals who are prone to such infection and those who are not, US researchers have shown.

16 Jun 2014

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer.

10 Jun 2014

Researchers develop antibodies that reduce liver damage, recovers liver function

A Tainan-based research team from National Cheng Kung University (NCKU) has discovered the pathogenesis of liver fibrosis and developed antibodies that reduce liver damage, inhibit hepatic fibrosis, and recover liver function.

4 Jun 2014

Biovision provides list of businesses, projects selected for Investor Conference and Catalyzer sessions

Biovision, the annual forum on future-oriented research in life sciences, today announces the list of biotech and medtech companies and projects selected for the Investor Conference and Catalyzer sessions. Awards will be presented during the closing ceremony.

20 May 2014

Innate immune response may warn of chronic multisite musculoskeletal pain

An enhanced innate immune response may be an indicator of the onset or prolongation of chronic, multisite musculoskeletal pain, cross-sectional study findings suggest.

19 May 2014

IL-8 expression predicts lung adenocarcinoma prognosis

Interleukin -8 expression is associated with a poor lung adenocarcinoma prognosis, say Japanese researchers, especially in patients whose tumours are positive for the KRAS mutation.

19 May 2014

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results and operational highlights for the quarter ended March 31, 2014.

15 May 2014

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

AstraZeneca today announced that MedImmune, its global biologics research and development arm, will present Phase IIb data on two novel investigational molecules – benralizumab and tralokinumab – at the upcoming American Thoracic Society 2014 International Conference being held in San Diego, California, 16-21 May.

14 May 2014

Baylor receives $3.3M grant from NIAMS to advance research in autoimmune diseases

Baylor Research Institute has received a $3.3 million grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), one of the National Institutes of Health, to fund its Autoimmunity Center of Excellence.

14 May 2014

Researchers use natural molecule to treat type 2 diabetes

Researchers at the Universit- Laval Faculty of Medicine, the Quebec Heart and Lung Institute Research Center, and the Institute of Nutrition and Functional Foods have discovered a natural molecule that could be used to treat insulin resistance and type 2 diabetes.

13 May 2014

Inflammation may accentuate age-related bladder function decline

Age-associated biochemical changes in the bladder may accentuate the inflammation associated with overactive bladder, study findings indicate.

12 May 2014

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2014.

12 May 2014

Study: Anti-inflammatory compound interleukin-10 plays crucial role in regenerative, scarless healing

The powerful anti-inflammatory compound interleukin-10 (IL-10) plays a crucial role in regenerative, scarless healing of fetal skin.

9 May 2014

Genetic changes linked to altered default mode network in psychosis

Researchers have identified biological processes likely to underlie altered activity in the resting-state default mode network in patients with psychosis.

8 May 2014

RPCI research finds patients with metastatic kidney cancer benefit from HDIL-2 immunotherapy

A retrospective study published online ahead of print in the medical journal Urology by a physician team from Roswell Park Cancer Institute (RPCI) found that patients with metastatic kidney cancer — even those with chronic renal insufficiency — can tolerate and benefit from a treatment called high-dose interleukin-2 (HDIL-2) immunotherapy.

7 May 2014